Doing it our way now: the approach this company pioneered is becoming the market's way
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes that their way of doing things is being adopted, copied, or moved toward by others in the market, and that they treat it as validation. Scan the transcript for relevant statements. Chad Robins says: "I actually think even a lot of the noise around MRD and solid tumors, and just kind of a nomenclature and understanding kind of what the assay is, and no one wants to be first, but no one else wants to be last. And we're kind of hitting that starting to, I would say, starting to hit that point where it's become kind of more common practice." This suggests that MRD testing is becoming more common practice, but is that specifically about Adaptive's way? It's about MRD in general, not necessarily that others are copying Adaptive's specific approach. Also, it's more about the market adopting MRD testing, not necessarily copying Adaptive's specific method. The question asks if others are adopting the company's way of doing things. Here, it's more about the general acceptance of MRD as a concept, not specifically that competitors are copying Adaptive's clonoSEQ. Also, management doesn't explicitly say competitors are following their lead. They mention "no one wants to be first, but no one else wants to be last" which implies others are now adopting MRD, but it's not clear that they are copying Adaptive's specific technology. Also, they don't treat it as validation of their lead; they just note it's becoming common practice. The question requires that management describes others adopting their specific way, and that they treat it as confirming their position. Here, it's more about the market moving toward MRD in general, not necessarily copying Adaptive's specific approach. Also, they don't say "others are trying to replicate what we do" or anything like that. So likely NO. Check other parts: They talk about being the gold standard, but that's a claim, not evidence of others copying. They mention "we have built strong moats" but that's differentiation. No mention of competitors launching similar products or adopting their methods. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| USFD | US Foods Holding Corp. | Q1 2018 | 2018-05-12 | C |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
AES · Q1 2024 → YESThe question is: Does management describe that the WAY THIS COMPANY DOES THINGS is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is ...
GGR · Q1 2023 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?
TGT · Q4 2022 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?